Business
BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models
BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Prec...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, Sept. 18, 2017\n\n\n\n- BELLUS to provide BLU-5937 program update during September 20th webcast -- Key Opinion Leader Dr. Jacky Smith to present on chronic cough -\n\n\n\nLAVAL, QC, Sept. 18, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that its P2X3 antagonist drug candidate for chronic cough, BLU-5937, has shown a significant reduction in cough and no taste disturbance in two separate preclinical models. In the guinea pig cough model, BLU-5937 has shown comparable efficacy to the current leading P2X3 antagonist, Merck & Co's Gefapixant (also named AF-219 or MK-7264). In the rat taste model, BLU-5937 did not inhibit taste; however, consistent with clinical trial data previously presented by Merck & Co, Gefapixant did significantly impact taste. \n\n\"These preclinical data further support BLU-5937 as a potential best in P2X3 class anti-tussive drug that reduces cough with little or no taste effect,\" said Roberto Bellini, President and CEO of BELLUS Health. \"We're looking forward to discussing these data in more detail and have KOL Dr. Smith present on the chronic cough therapeutic landscape during our September 20th event.\" \n\nThe Company's BLU-5937 program update and Key Opinion Leader (KOL) event will be webcast live on Wednesday September 20, 2017 at 2:00 pm Eastern Time. KOL Dr. Jacky Smith, Professor of Respiratory Medicine at the University of Manchester and Director of the NIHR South Manchester Respiratory and Allergy Clinical Research Facility, will discuss the clinical presentation of chronic cough, its current unmet medical need and therapeutic options, as well as novel treatment approaches under development. \n\nDr. Denis Garceau, BELLUS Health's Senior Vice President, D...